Zoetis (ZOE) AI Stock Analysis

0 Followers

Zoetis

(BX Swiss:ZOE)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High Profitability and Cash GenerationZoetis combines high margins with substantial operating and free cash flow, indicating that earnings are strongly cash-backed. This financial capacity supports research, commercial investment, dividends, and repurchases while helping the company sustain its competitive position through normal market cycles.

Negative Factors

Companion Animal and Dermatology PressureCompanion-animal weakness, especially dermatology competition and Apoquel share loss, is affecting a strategically important product area. Persistent pressure could restrain revenue and earnings growth until newer products scale and the company stabilizes market share.

Zoetis Business Overview & Revenue Model

Company Description

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of...

Zoetis Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|Next Earnings Date:Feb 16, 2027

Earnings Call SentimentNeutral

The call reflected a mixed outlook. Zoetis demonstrated resilience through livestock growth, diagnostics momentum, portfolio diversity, promotional share defense, raised earnings guidance, and continued pipeline progress. However, near-term performance remained pressured by declines in companion animal revenue, dermatology competition, generic erosion, softer clinic visits, affordability concerns, lower gross margin, and cautious 2027 assumptions. The positive execution and longer-term innovation opportunities were balanced by significant current-market challenges.

Positive Updates

Revenue Performance Met Expectations and Guidance Was Narrowed

Third-quarter revenue was $2.4 billion, declining 1% on both a reported and organic operational basis, in line with expectations. The company narrowed its full-year 2026 revenue guidance to $9.22 billion-$9.32 billion, representing an organic operational decline of -2% to -1% year over year, to the high end of its prior range.

Negative Updates

Quarterly Revenue and Adjusted Net Income Declined

Third-quarter revenue declined 1% to $2.4 billion, while adjusted net income declined 7% on an organic operational basis to $720 million.

Company Guidance

For 2026, Zoetis narrowed full-year revenue guidance to $9.22 billion-$9.32 billion, representing an organic operational decline of -2% to -1% year over year, raised adjusted net income guidance to $2.6 billion-$2.64 billion, representing organic operational decline of -7% to -5%, and raised adjusted diluted EPS to $6.25 to $6.35; the company anticipates a third to fourth quarter decline in the high single-digit range, expects approval of Cytopoint long-acting this year and to launch it in the first half of next year, expects approval of Simparica Duo by year-end and launch it next year, and expects approval of Lenivia in the U.S. in 2027, while it is too early to provide specific guidance for 2027, will not assume improvements in the macro environment or pet owner spending trends, expects competitive dynamics to remain a factor throughout most of the year, and expects limited revenue contribution from the 2027 and 2028 launches in 2027, with their impact building later in the year and into 2028.

Zoetis Risk Analysis

Zoetis disclosed 51 risk factors in its most recent earnings report. Zoetis reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Zoetis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:ZOE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELAN	67Neutral	$13.38B	-88.27	-2.24%	―	12.13%	-507.13%
PAHC	66Neutral	$1.41B	13.84	27.44%	1.37%	10.10%	51.28%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

CH:ZOE and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	PAHC	Phibro Animal Health Corp	35.15	-9.00	-20.39%
	ELAN	Elanco Animal Health	26.48	4.49	20.42%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Zoetis AI Stock Analysis